SCHEMBL22719369

SCHEMBL22719369

N#CC1(Cc2cccc(Cl)c2)CCN(C(=O)c2cccnc2-c2ccncn2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP46A1 Q9Y6A2 9/20 0.61
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2C8 P10632 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ ALDH1A1 P00352 4/20 0.37
▸ KDM4E B2RXH2 3/20 0.37
▸ HTT P42858 2/20 0.37
▸ TSHR P16473 2/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ CHRM2 P08172 1/20 0.36
▸ CHRM3 P20309 1/20 0.36
▸ USP2 O75604 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ P2RX7 Q99572 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29453776 1.00 CYP46A1 (0.61) CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19
SCHEMBL22719288 0.91 CYP46A1 (0.64) CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19
SCHEMBL29453691 0.91 CYP46A1 (0.64) CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19
SCHEMBL22719440 0.89 CYP46A1 (0.76) CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19
SCHEMBL24710206 0.89 CYP46A1 (0.59) CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19
SCHEMBL22719424 0.88 CYP46A1 (0.59) CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19
SCHEMBL29453742 0.88 CYP46A1 (0.59) CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19
SCHEMBL22719439 0.88 CYP46A1 (0.59) CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19
SCHEMBL22719171 0.88 CYP46A1 (0.59) CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19
SCHEMBL29453798 0.88 CYP46A1 (0.59) CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022261510-A1 NEUROACTIVE STEROID FOR THE TREATMENT OF ALZHEIMER'S DISEASE SAGE THERAPEUTICS, INC. (US) 2022-12-15 — — WO disclosed
US-20220332699-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USE SAGE THERAPEUTICS, INC. 2022-10-20 — — US disclosed
WO-2020243027-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USE SAGE THERAPEUTICS, INC. (US) 2020-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332699-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USE CYP46A1, CYP26A1, CYP21A2 CYP46A1 1/4885CYP3A4 35/4885CYP2C8 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback